United Therapeutics (UTHR) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
4 Nov, 2026Executive summary
Q3 revenue reached a record $832.5M, up 4% YoY; net income fell 24% to $258.6M and diluted EPS declined to $5.71 from $7.16.
Commercial momentum and a broad cardiopulmonary and respiratory strategy span 14 development programs, including manufactured-organ alternatives.
Financial highlights
Q3 operating income was $307.8M versus $388.5M; operating expenses rose to $524.7M from $411.0M.
R&D expense increased 119% to $279.2M, including Thymmune and manufactured-organ and cardiopulmonary spending; SG&A fell to $146.4M, including a $66.5M litigation-accrual reversal.
9M revenue was $2,397.3M versus $2,392.5M; operating income was $964.4M versus $1,135.8M, and net income was $866.5M versus $970.4M.
TTM operating cash flow was $1.4B; cash, cash equivalents and marketable investments totaled $3,535.7M at September 30, 2026.
Outlook and guidance
Management described the growth outlook as the strongest in its history; expanded commercial resources are expected to support growth in Q4 and 2027.
FDA PDUFA dates are April 26, 2027 for nebulized Tyvaso in IPF and June 24, 2027 for oral ralinepag in PAH; ralinepag timing depends on resolving API manufacturing deficiencies.
TETON-PPF enrolled 754 patients against a 698-patient target; topline data are expected in 2H 2027.
Soft-mist inhaler NDA filing is expected in 2027 after additional data generation; development-partner work is underway to update the timeline.
Growth drivers include Tyvaso DPI, increased PH-ILD prescribing, potential ralinepag and IPF launches, Orenitram growth and modest price increases.
Latest events from United Therapeutics
- Record commercial performance sets up a busy 2027 of FDA decisions and pipeline milestones.UTHR
Jefferies Global Healthcare Conference - Record TYVASO momentum and multiple 2027 pipeline catalysts define the outlook.UTHR
UBS Global Biopharma Conference 2026 - Expanding into pulmonary fibrosis with strong clinical data and major revenue growth targets.UTHR
Morgan Stanley 24th Annual Global Healthcare Conference - Disruptive therapies and organ manufacturing drive exponential growth and innovation.UTHR
Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum - Pulmonary fibrosis breakthroughs and 14 launches drive a projected 10x revenue surge.UTHR
12th Annual Cantor Fitzgerald Global Healthcare Conference - Aggressive product launches and innovation aim for $50–100B revenue and industry leadership.UTHR
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenues fell 2% to $783.3M, but net income rose 8% to $333M on Tyvaso DPI growth.UTHR
Q2 2026 - Record growth, breakthrough pulmonary fibrosis results, and pioneering xenotransplantation trials.UTHR
Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum - Q2 2024 revenue up 20% to $715M, net income $278.1M, Tyvaso led growth, $1B buyback completed.UTHR
Q2 2024